drugset / Trial / NCT00044993

Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer

NCT00044993

Phase 2 Completed Introgen Therapeutics
Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Inserting the p53 gene into the tumor may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. Combining chemotherapy with gene therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy with gene therapy in treating patients who have stage III or stage IV breast cancer.

Timeline

Start
2002-02
Primary completion
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CONTUSUGENE LADENOVEC Unknown Other
Subject Docetaxel Small molecule Intravenous
Subject Doxorubicin Other / unclassified Intravenous

Indications